SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova reports many fold jump in Q1 consolidated net profit

19 Jul 2024 Evaluate

Jubilant Pharmova has reported results for first quarter ended June 30, 2024 (Q1FY25). 

The company has reported net loss at Rs 10.20 crore for the quarter ended June 30, 2024 as compared to net profit of Rs 1.90 crore for the same quarter in the previous year. Total income of the company decreased by 20.18% at Rs 186.20 crore for Q1FY25 as compared to Rs 233.30 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported many fold jump in net profit at Rs 481.80 crore for Q1FY25 as compared to Rs 6.00 crore for the same quarter in the previous year. Total income of the company increased by 9.41% at Rs 1745.70 crore for Q1FY25 as compared to Rs 1595.50 crore for the corresponding quarter previous year.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×